ClinVar Miner

Submissions for variant NM_003119.4(SPG7):c.2096dup (p.Met699fs) (rs747503698)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Athena Diagnostics Inc RCV000489898 SCV000844100 pathogenic not provided 2018-05-30 criteria provided, single submitter clinical testing
GeneDx RCV000489898 SCV000577548 pathogenic not provided 2018-11-27 criteria provided, single submitter clinical testing The c.2096dupT pathogenic variant in the SPG7 gene causes a frameshift starting with codon Methionine 699, changes this amino acid to an Isoleucine residue and creates a premature Stop codon at position 4 of the new reading frame, denoted p.Met699IlefsX4. This pathogenic variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. Furthermore, the c.2096dupT variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). Although this pathogenic variant has not been previously reported to our knowledge, other truncating variants in the SPG7 gene have been reported in association with spastic paraplegia (Stenson et al., 2014). Therefore, c.2096dupT is considered a pathogenic variant.
Illumina Clinical Services Laboratory,Illumina RCV000460135 SCV000914745 uncertain significance Spastic paraplegia 7 2018-10-11 criteria provided, single submitter clinical testing This variant results in a frameshift and is predicted to result in premature termination of the protein. It was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018) and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score for this variant, it could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene and cDNA change, and amino acid change. No publications were found based on this search. Due to the potential impact of frameshift variants and the lack of clarifying evidence, this variant is classified as a variant of unknown significance but suspicious for pathogenicity for this disease.
Invitae RCV000460135 SCV000552956 pathogenic Spastic paraplegia 7 2018-11-08 criteria provided, single submitter clinical testing This sequence change inserts 1 nucleotide in exon 15 of the SPG7 mRNA (c.2096dupT), causing a frameshift at codon 699. This creates a premature translational stop signal (p.Met699Ilefs*4) and is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in SPG7 are known to be pathogenic (PMID: 22964162). For these reasons, this variant has been classified as Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.